Related Experiment Video
Updated: May 10, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
New paradigm for drug developments--from emerging market statistical perspective.
1Biostatistics and Programming, Sanofi, Bridgewater, NJ 08807, United States.
Contemporary Clinical Trials
|July 2, 2013
Summary
New drug development is longer and costlier despite technological advances. Pharmaceutical companies are offshoring biostatistical support to emerging markets like China to manage costs and find talent.
Area of Science:
- Pharmaceutical industry
- Drug development
- Biostatistics
Background:
- The drug development paradigm has shifted, with increased costs and timelines.
- Stringent regulatory requirements and technological advancements impact efficiency.
- Pharmaceutical companies are exploring strategies to mitigate rising development costs.
Purpose of the Study:
- To discuss the evolving skill set required for trial statisticians.
- To explore methods for acquiring statistical talent in emerging markets.
- To recommend strategies for leveraging emerging market statistical capacity.
Main Methods:
- Analysis of current trends in pharmaceutical R&D offshoring.
- Discussion of skill requirements for modern trial statisticians.
- Exploration of talent acquisition strategies in emerging economies.
Main Results:
- Major pharmaceutical companies are increasingly offshoring biostatistical support to China.
- Emerging markets present opportunities for cost-effective statistical capacity building.
- Adaptation of statistical roles and talent acquisition is crucial.
Conclusions:
- Offshoring biostatistical support to emerging markets is a key cost-containment strategy.
- Developing statistical talent in emerging markets is vital for the industry.
- Collaboration between industry, health authorities, and academia is recommended.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...